Skip to main content
Midas Edge

Crinetics Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Checking your notes…

FORM 10-K — ANNUAL REPORT

For the Fiscal Year Ended December 31, 2025

Page
Defined Termsi
PART I
Item 1Business4
Item 1ARisk Factors24
Item 1BUnresolved Staff Comments66
Item 1CCybersecurity66
Item 2Properties67
Item 3Legal Proceedings67
Item 4Mine Safety Disclosures67
PART II
Item 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities68
Item 6[Reserved]68
Item 7Management’s Discussion and Analysis of Financial Condition and Results of Operations69
Item 7AQuantitative and Qualitative Disclosures About Market Risk77
Item 8Financial Statements and Supplementary Data78
Item 9Changes in and Disagreements with Accountants on Accounting and Financial Disclosure78
Item 9AControls and Procedures78
Item 9BOther Information81
Item 9CDisclosure Regarding Foreign Jurisdictions that Prevent Inspections81
PART III
Item 10Directors, Executive Officers and Corporate Governance82
Item 11Executive Compensation82
Item 12Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters82
Item 13Certain Relationships, Related Transactions and Director Independence82
Item 14Principal Accounting Fees and Services82
PART IV
Item 15Exhibits, Financial Statement Schedules83
Signatures

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.